09:48 AM EST - Aleafia Health Inc. : Announced that Janssen Pharmaceuticals, Inc., has approved its wholly owned subsidiary, Canabo Medical Inc. as an administrator and prescriber of antidepressant SPRAVATO® (esketamine) nasal spray. Three Canabo clinics, including the Company’s flagship Toronto location, along with a growing number of clinic network physicians and nurses, are now approved to administer and prescribe SPRAVATO® following the Janssen Journey training program’s completion. The Company intends to further expand this offering at its nationwide network of clinics and education centres which are staffed by physicians and nurse practitioners and have served over 70,000 unique patients to date. Aleafia Health Inc.
shares T.AH are trading up $0.04 at $0.61.
